A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
06 01 2021
Historique:
received: 09 09 2020
accepted: 16 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 6 8 2021
Statut: epublish

Résumé

Intradialytic hypotension (IDH) is a frequent complication of intermittent hemodialysis (IHD), occurring from 15 to 50% of ambulatory sessions, and is more frequent among hospitalized patients with hypoalbuminemia. IDH limits adequate fluid removal and increases the risk for vascular access thrombosis, early hemodialysis (HD) termination, and mortality. Albumin infusion before and during therapy has been used for treating IDH with the varying results. We evaluated the efficacy of albumin infusion in preventing IDH during IHD in hypoalbuminemic inpatients. A randomized, crossover trial was performed in 65 AKI or ESKD patients with hypoalbuminemia (albumin < 3 g/dl) who required HD during hospitalization. Patients were randomized to receive 100 ml of either 0.9%sodium chloride or 25% albumin intravenously at the initiation of each dialysis. These two solutions were alternated for up to six sessions. Patients' vital signs and ultrafiltration removal rate were recorded every 15 to 30 min during dialysis. IDH was assessed by different definitions reported in the literature. All symptoms associated with a noted hypotensive event as well as interventions during the dialysis were recorded. Sixty-five patients were submitted to 249 sessions; the mean age was 58 ([Formula: see text] 12), and 46 (70%) were male with a mean weight of 76 ([Formula: see text] 18) kg. The presence of IDH was lower during albumin sessions based on all definitions. The hypotension risk was significantly decreased based on the Kidney Disease Outcomes Quality Initiative definition; (15% with NS vs. 7% with albumin, p = 0.002). The lowest intradialytic SBP was significantly worse in patients who received 0.9% sodium chloride than albumin (NS 83 vs. albumin 90 mmHg, p = 0.035). Overall ultrafiltration rate was significantly higher in the albumin therapies [NS - 8.25 ml/kg/h (- 11.18 5.80) vs. 8.27 ml/kg/h (- 12.22 to 5.53) with albumin, p = 0.011]. In hypoalbuminemic patients who need HD, albumin administration before the dialysis results in fewer episodes of hypotension and improves fluid removal. Albumin infusion may be of benefit to improve the safety of HD and achievement of fluid balance in these high-risk patients. ClinicalTrials.gov Identifier: NCT04522635.

Sections du résumé

BACKGROUND
Intradialytic hypotension (IDH) is a frequent complication of intermittent hemodialysis (IHD), occurring from 15 to 50% of ambulatory sessions, and is more frequent among hospitalized patients with hypoalbuminemia. IDH limits adequate fluid removal and increases the risk for vascular access thrombosis, early hemodialysis (HD) termination, and mortality. Albumin infusion before and during therapy has been used for treating IDH with the varying results. We evaluated the efficacy of albumin infusion in preventing IDH during IHD in hypoalbuminemic inpatients.
METHODS
A randomized, crossover trial was performed in 65 AKI or ESKD patients with hypoalbuminemia (albumin < 3 g/dl) who required HD during hospitalization. Patients were randomized to receive 100 ml of either 0.9%sodium chloride or 25% albumin intravenously at the initiation of each dialysis. These two solutions were alternated for up to six sessions. Patients' vital signs and ultrafiltration removal rate were recorded every 15 to 30 min during dialysis. IDH was assessed by different definitions reported in the literature. All symptoms associated with a noted hypotensive event as well as interventions during the dialysis were recorded.
RESULTS
Sixty-five patients were submitted to 249 sessions; the mean age was 58 ([Formula: see text] 12), and 46 (70%) were male with a mean weight of 76 ([Formula: see text] 18) kg. The presence of IDH was lower during albumin sessions based on all definitions. The hypotension risk was significantly decreased based on the Kidney Disease Outcomes Quality Initiative definition; (15% with NS vs. 7% with albumin, p = 0.002). The lowest intradialytic SBP was significantly worse in patients who received 0.9% sodium chloride than albumin (NS 83 vs. albumin 90 mmHg, p = 0.035). Overall ultrafiltration rate was significantly higher in the albumin therapies [NS - 8.25 ml/kg/h (- 11.18 5.80) vs. 8.27 ml/kg/h (- 12.22 to 5.53) with albumin, p = 0.011].
CONCLUSION
In hypoalbuminemic patients who need HD, albumin administration before the dialysis results in fewer episodes of hypotension and improves fluid removal. Albumin infusion may be of benefit to improve the safety of HD and achievement of fluid balance in these high-risk patients. ClinicalTrials.gov Identifier: NCT04522635.

Identifiants

pubmed: 33407747
doi: 10.1186/s13054-020-03441-0
pii: 10.1186/s13054-020-03441-0
pmc: PMC7789619
doi:

Substances chimiques

Albumins 0

Banques de données

ClinicalTrials.gov
['NCT04522635']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States

Références

Am J Kidney Dis. 1999 Jun;33(6):1107-14
pubmed: 10352199
N Engl J Med. 2008 Jul 3;359(1):7-20
pubmed: 18492867
Blood Purif. 2010;29(3):245-51
pubmed: 20016148
Int Urol Nephrol. 2006;38(3-4):701-5
pubmed: 17160633
Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006758
pubmed: 21069691
Acta Anaesthesiol Scand. 2018 Aug;62(7):936-944
pubmed: 29664109
Crit Care. 2016 Jun 09;20(1):140
pubmed: 27277830
J Am Soc Nephrol. 2015 Mar;26(3):724-34
pubmed: 25270068
Kidney Int. 2009 Aug;76(4):422-7
pubmed: 19436332
Artif Organs. 2003 Sep;27(9):772-80
pubmed: 12940898
Crit Care Med. 1982 Oct;10(10):650-2
pubmed: 7116885
Am J Kidney Dis. 2018 Jul;72(1):136-148
pubmed: 29478864
Am J Respir Crit Care Med. 2000 Jul;162(1):197-202
pubmed: 10903241
J Intensive Care Soc. 2017 Nov;18(4):282-288
pubmed: 29123557
Crit Care. 2016 Jun 23;20(1):196
pubmed: 27334608
Hemodial Int. 2009 Jul;13(3):293-300
pubmed: 19469884
Clin J Am Soc Nephrol. 2020 Oct 28;:
pubmed: 33115729
Kidney Int. 2002 Sep;62(3):1075-80
pubmed: 12164893
Crit Care. 2013 Jan 24;17(1):R14
pubmed: 23347825
Nephrol Dial Transplant. 2013 Feb;28(2):430-7
pubmed: 22535635
Am J Nephrol. 2012;36(2):168-74
pubmed: 22846598
Semin Dial. 2009 Sep-Oct;22(5):472-5
pubmed: 19522759
Pilot Feasibility Stud. 2019 May 30;5:72
pubmed: 31161046
Blood Purif. 2018;45(1-3):230-235
pubmed: 29478062
Pediatr Nephrol. 2017 Feb;32(2):341-345
pubmed: 27553912
J Am Soc Nephrol. 2004 Feb;15(2):487-92
pubmed: 14747397
J Hypertens. 2010 Feb;28(2):314-24
pubmed: 19927010

Auteurs

Etienne Macedo (E)

Department of Medicine, Division of Nephrology, University of California San Diego, San Diego, CA, USA. emmacedo@ucsd.edu.

Bethany Karl (B)

Department of Medicine, Division of Nephrology, University of California San Diego, San Diego, CA, USA.

Euyhyun Lee (E)

Altman Clinical and Translational Research Institute, UC San Diego, La Jolla, CA, USA.

Ravindra L Mehta (RL)

Department of Medicine, Division of Nephrology, University of California San Diego, San Diego, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH